Innovation Pharmaceuticals Inc (IPIX)

[threebabiesbusy]

IPI-BRIc-201
Protocol name
Double-blind, placebo-controlled, randomized, multicenter Phase II study to evaluate the efficacy and safety of Brilacidin in patients hospitalized with COVID-19
Therapeutic area
Anesthesiology and resuscitation, Infectious diseases, Oncology, Therapy (general), Surgery, Cardiology, Pulmonology, Toxicology
CI start and end date
12/17/2020 - 03/31/2021
RCT number and date
No. 705 dated 12/17/2020
Organization conducting CT
Innovation Pharmaceuticals Inc. (Innovation Pharmaceuticals Inc.)
Drug name
Brilacidin
Dosage form and dosage
solution for intravenous administration, 50 mg / ml
Cities
Barnaul, Kirovsk, Moscow, Nizhny Novgorod, Ryazan, St. Petersburg, Saratov, Yaroslavl
Developer country
USA
Organization involved by the drug developer
IPharma LLC, 143026, Moscow, the territory of the Skolkovo innovation center, st. Nobel, 7, Russia
CI phase
II
KI type
IMCI
The purpose of CI
assessment of the efficacy and safety of Brilacidin in patients hospitalized with COVID-19
Number of medical institutions
20
Number of patients
106